about
The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancerComparison of treatment and outcome information between a clinical trial and the National Cancer Data Repository.Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group.Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life.Timing of breast cancer surgery in relation to menstrual cycle phase: no effect on 3-year prognosis: the ITS Study.Short-term costs of conventional vs laparoscopic assisted surgery in patients with colorectal cancer (MRC CLASICC trial).CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and TreatmentPanitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.Adhesions and incisional hernias following laparoscopic versus open surgery for colorectal cancer in the CLASICC trial.The metastatic microenvironment of breast cancer: clinical implications.Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.Tumor Deposits in Colorectal Cancer: Improving the Value of Modern Staging-A Systematic Review and Meta-Analysis.The impact of postoperative complications on long-term quality of life after curative colorectal cancer surgery.Hand aging: patients' opinions.A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO).Laparoscopically assisted vs open colectomy for colon cancer: a meta-analysis.An international, multicentre, prospective, randomised, controlled, unblinded, parallel-group trial of robotic-assisted versus standard laparoscopic surgery for the curative treatment of rectal cancer.Breast-cancer adjuvant therapy with zoledronic acid.Patient factors influencing conversion from laparoscopically assisted to open surgery for colorectal cancer.Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial.Effect of Robotic-Assisted vs Conventional Laparoscopic Surgery on Risk of Conversion to Open Laparotomy Among Patients Undergoing Resection for Rectal Cancer: The ROLARR Randomized Clinical Trial.Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04).Lymph nodes, tumor deposits, and TNM: are we getting better?A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO).Modelling residual disease volume and re-growth rates from response durations to aid in cancer trial design, interpretation and analysis, with a particular focus on breast cancer.Testosterone replacement in young male cancer survivors (TRYMS) - pragmatic adaptation of trial design for a trial struggling with recruitment.TRYMS: the ethical and practical considerations of a double-blind placebo controlled randomised clinical trial.Optimising trial monitoring on the AZURE trial.Statistical issues in the design of randomised surgical trials: a practical example of the possible solutions.Reproductive hormone analyses and effects of adjuvant zoledronic acid in early breast cancer - An AZURE (BIG 01/04) sub-study.Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial.Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial.Minimization--reducing predictability for multi-centre trials whilst retaining balance within centre.Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study.Feasibility of a multicentre, randomised controlled trial of laparoscopic versus open colorectal surgery in the acute setting: the LaCeS feasibility trial protocol.Refining systemic therapy for early breast cancer: difficulties with subtraction.Reliability of pressure ulcer classification and diagnosis.Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.Exploring and adjusting for potential learning effects in ROLARR: a randomised controlled trial comparing robotic-assisted vs. standard laparoscopic surgery for rectal cancer resection.Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)
P50
Q24597847-06D1BA83-35BE-4D7B-AE3F-AA19BAA60F68Q33730432-24D18597-0D4C-4080-9891-29DC50113931Q34581139-4D46AE3A-972B-48C4-B1D2-F55D77F288EFQ35536245-542AF0EA-4362-412B-AAAC-A15E601B0AA1Q36608823-6711106A-177F-46E7-9168-F7779C76B389Q36611611-7952F9BF-0099-4AF1-8C2C-2296DD9F9368Q36731411-C074C7E5-87A7-40E2-B3B0-EFC55CDD4F1BQ36977022-FC888C5E-EF78-431C-BBBF-8D192E3563F0Q37655932-460059C1-2440-4A46-AC83-2D0504519009Q38145832-1EC1AA28-01AB-4437-9269-00D36DB73DA8Q38230839-C281886D-2B39-4406-8B8D-30F8CE71B666Q39060186-F1A89B67-B712-4B00-BE87-C85C329A1415Q39283473-495841C1-05B2-4ACB-9CA4-8939B3F3FD38Q39758850-63603003-2F3E-4ED2-98C2-CA9828D2DBD1Q40377448-55911F54-1CC2-4DEA-A180-1E9450C5C511Q42615123-74436FA5-59DA-405D-8E2C-B693DC4AA457Q42616134-02309C59-D471-4E8D-ADEE-BC94A24DDC18Q42620139-CED76FCB-FFF1-4EB1-B52E-CF643E310678Q42628893-01993780-6393-4E88-B5AE-7EB737F01A73Q42656476-471780B4-A811-4FBB-9DE0-462D69195A97Q42698996-C2C485B9-08EC-4D7C-B07D-E01DDA0F65DBQ43844327-DF6C0D29-F496-40E4-A5BE-D20FB5692A8EQ43868593-6DECBEBD-FD2A-483C-B93D-A5441C1C820EQ44547612-C7ED0F89-B7B7-43CA-9BBC-6B0CA92F9574Q45895489-28EE7AEB-8050-48F4-BF3B-5061AB3C46ACQ45979029-8593AB21-42B6-4039-B879-3F2778913066Q45991621-3191FD46-C1A7-4BCA-A1F4-5FC1546A33C9Q46680302-A9AF325F-B4A1-45D2-8FCB-3B8AED3BC3A2Q46742318-E453BB35-F6FC-4C80-805F-E95B04B08D47Q47110989-2D40617D-DDF5-4591-B0F0-B0C68DF995DDQ47644628-8170FCB1-07A1-4813-BBAC-13BDE00B1AC5Q50051344-65A6543D-7FC1-4122-A8A6-0E025B918219Q51959060-EE741E0E-BAB6-496C-8722-D25ABA2FAF06Q52653865-308399B3-A157-402F-A1D5-479FCD2A0211Q52803396-6AA573C8-F77B-446A-A119-ED5B97598C17Q52849183-F3201170-16EF-4A9E-AE0D-48ADFD36E1EAQ52857852-1418B610-F669-4EA2-B626-3533506406E8Q53434420-FA9A2B5F-635F-4CEA-ADDB-8BCD630F9B2DQ55432606-F4E661E1-57DC-4011-AA54-EFE203ACEF9DQ57954344-50A7C426-50F9-4862-A6A3-3A097FF948C8
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
researcher
@en-gb
հետազոտող
@hy
name
Helen Marshall
@ast
Helen Marshall
@en
Helen Marshall
@en-gb
Helen Marshall
@es
Helen Marshall
@nl
Helen Marshall
@sl
type
label
Helen Marshall
@ast
Helen Marshall
@en
Helen Marshall
@en-gb
Helen Marshall
@es
Helen Marshall
@nl
Helen Marshall
@sl
altLabel
Helen Thorpe
@en
prefLabel
Helen Marshall
@ast
Helen Marshall
@en
Helen Marshall
@en-gb
Helen Marshall
@es
Helen Marshall
@nl
Helen Marshall
@sl
P106
P1153
57203054136
P21
P31
P496
0000-0003-0944-0152